What Is Thymosin Alpha-1 (Thymalfasin)? Definition and What Research Reports
Thymalfasin is the nonproprietary name for synthetic thymosin alpha-1 (Tα1), a small acetylated peptide originally characterised from thymus tissue and studied as an immune-modulating agent. In the literature it is used mainly as a research and clinical immunomodulator rather than a growth or metabolic peptide. Published work reports effects on T cells, macrophage polarisation and cytokine output in laboratory and clinical settings, alongside at least one negative finding in cystic fibrosis airway models. This entry is definitional and does not describe use.
Definition
Thymalfasin is the nonproprietary (generic) name used for the synthetic form of thymosin alpha-1, abbreviated Tα1 — a small, naturally occurring peptide first characterised from thymus tissue extracts and studied for decades as an immune-modulating molecule. Reviews describe Tα1 as a 28-amino-acid, N-terminally acetylated peptide derived from the larger precursor protein prothymosin alpha, and position it as an endogenous immunoregulator rather than a hormone with a single target organ (PMID 41373628). In practice, "thymalfasin" and "thymosin alpha-1" are used interchangeably in much of the published literature, with the former appearing more often in clinical and regulatory contexts and the latter in basic immunology papers.
What Class of Molecule It Is, and Where It Comes From
Thymosin alpha-1 belongs to the thymosin family of peptides, a group originally isolated from thymic extracts (historically "thymosin fraction 5"). Because it is a short peptide rather than a protein or a small molecule, the synthetic version used in research is produced by chemical peptide synthesis. Review literature frames Tα1 as part of the thymus-derived signalling repertoire that shapes T-lymphocyte maturation and innate immune tone, and connects declining thymic function with age to interest in Tα1 as a probe of immunosenescence (PMID 41373628).
Tα1 is also measurable in human serum. One 2016 investigation measured circulating thymosin α1 and reported lower serum concentrations in patients with chronic inflammatory autoimmune diseases compared with healthy controls, which the authors discussed as evidence that endogenous Tα1 levels track with immune dysregulation (PMID 27350088).
| Field | Entry |
|---|---|
| Term | Thymalfasin |
| Also called | Thymosin alpha-1, Tα1, thymosin α1 |
| Molecule class | Short synthetic peptide (28 amino acids, acetylated N-terminus) (PMID 41373628) |
| Origin of the natural form | Thymus-derived; fragment of the precursor prothymosin alpha (PMID 41373628) |
| Primary research framing | Immunomodulator — T cells, macrophages, cytokine signalling (PMID 36871535) |
| Common study settings | Cell lines, animal tumour models, human blood cells ex vivo, clinical trials in infection and oncology contexts |
How the Term Is Used in Peptide Research
Within peptide literature, thymalfasin is categorised as an immunomodulatory peptide. That distinguishes it from secretagogues, metabolic peptides or repair-oriented sequences: papers on Tα1 generally measure immune-cell phenotypes, cytokine profiles or infection and tumour outcomes rather than body composition or tissue healing endpoints. A 2023 review in the immuno-oncology space argued for reframing Tα1 beyond its historical antiviral associations and toward broader immunoregulatory applications, and summarised the mechanistic literature around antigen presentation, T-cell function and innate receptor signalling (PMID 36871535). A companion review the same year catalogued the immunoregulatory mechanisms attributed to Tα1 in cancer therapy and the settings in which it has been investigated as an adjunct (PMID 36812669).
Terminology note: "thymalfasin" is the name that appears on approved and registered pharmaceutical products in the jurisdictions where such products exist, while peptides sold as research chemicals are labelled research-use-only and are not approved medicines. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or a specific compound.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
Macrophage and T-cell effects in laboratory models
A substantial share of recent Tα1 work is preclinical immunology. A 2022 study in Cancer Research reported that thymosin α-1 reversed M2 polarisation of tumour-associated macrophages during efferocytosis, shifting macrophage phenotype in a direction the authors associated with improved antitumour immunity (PMID 35364609). A 2024 report in Cell Reports Medicine extended that theme to virotherapy, where researchers reported that Tα1 reversed oncolytic adenovirus-induced M2 polarisation of macrophages and improved antitumour immunity and therapeutic efficacy in the models tested (PMID 39357524).
On the T-cell side, a 2025 iScience study reported that interferon-α and thymosin-α1 combined with the checkpoint antibody tislelizumab enhanced CD8+ T-cell cytotoxicity toward pancreatic ductal adenocarcinoma in the experimental systems used (PMID 40727936). A separate 2025 paper characterised the immunomodulatory activity of thymosin alpha 1 across tumour cell lines and distinct immune-cell subsets, reporting that responses differed by cell type rather than following a single uniform pattern (PMID 40955371). An earlier engineering-oriented study described a modified thymosin alpha 1 construct and reported tissue distribution and inhibition of lung cancer growth in vivo in the animal model used (PMID 32426594).
Human cells and clinical settings
Two reports bear on human material. In a 2021 Open Forum Infectious Diseases study, researchers exposed blood cells from patients with coronavirus disease 2019 to thymosin alpha 1 and reported mitigation of the cytokine-storm profile in those ex vivo samples (PMID 33506065). In an older double-blind randomised controlled study in severe acute pancreatitis, the study reported that thymosin alpha 1 administration was associated with improved cellular immunity and a reduced infection rate among the patients enrolled (PMID 20549321). Neither report establishes a general-purpose profile; both are specific to their populations, endpoints and settings.
Negative and null findings
Balanced reading of a glossary entry requires the null results as well. A 2018 JCI Insight paper tested Tα1 in cystic fibrosis airway epithelia and reported that thymosin α-1 did not correct the F508del-CFTR defect in those models, a direct non-replication of an earlier claim about Tα1 acting as a single-molecule corrector (PMID 29415893). That result is frequently cited as a reminder that mechanistic breadth reported for an immunomodulator does not transfer automatically to unrelated disease biology.
Adverse Events: What Studies Report
The verified reports summarised on this page were designed around mechanism and efficacy endpoints rather than systematic safety characterisation, so they do not constitute a tolerability profile. The severe acute pancreatitis trial reported immune and infection-rate outcomes in its randomised design (PMID 20549321), and the cell-based and animal studies discussed above reported immunological and tumour-growth measures rather than adverse-event tallies (PMID 40955371). Absence of an adverse-event discussion in a mechanistic paper is not evidence of safety, and any question about risk belongs with a licensed clinician and the approved product labelling in the relevant jurisdiction.
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appHow to Read This Entry
- It is a definition, not a protocol. No dose, schedule or route is described here, because a glossary stub is not the place for it and because several of the cited papers are cell or animal work where no human dosing applies.
- Most recent evidence is preclinical. Macrophage-polarisation and CD8+ T-cell findings came from laboratory models (PMID 35364609, PMID 40727936).
- Reviews are summaries, not new data. The 2023 immuno-oncology reviews collated prior findings and proposed directions (PMID 36812669, PMID 36871535).
- Negative results exist. The cystic fibrosis airway work reported no correction of F508del-CFTR (PMID 29415893).
References
- Aging and Thymosin Alpha-1 (International Journal of Molecular Sciences, 2025)
- Thymosin alpha 1 — Reimagine its broader applications in the immuno-oncology era (International Immunopharmacology, 2023)
- Thymosin α-1 in cancer therapy: Immunoregulation and potential applications (International Immunopharmacology, 2023)
- Serum thymosin α1 levels in patients with chronic inflammatory autoimmune diseases (Clinical and Experimental Immunology, 2016)
- Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis (Cancer Research, 2022)
- Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy (Cell Reports Medicine, 2024)
- Interferon-α and thymosin-α1 plus tislelizumab enhance CD8(+) T cell cytotoxicity toward pancreatic ductal adenocarcinoma (iScience, 2025)
- The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets (OncoTargets and Therapy, 2025)
- Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo (ACS Omega, 2020)
- Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients (Open Forum Infectious Diseases, 2021)
- Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study (Inflammation, 2011)
- Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia (JCI Insight, 2018)
Frequently asked questions
Is thymalfasin the same thing as thymosin alpha-1?▾
Yes — thymalfasin is the nonproprietary name used for the synthetic form of thymosin alpha-1 (Tα1), and the two terms appear interchangeably in the literature. Reviews describe Tα1 as a 28-amino-acid acetylated peptide derived from the precursor prothymosin alpha and discuss it as an endogenous immunoregulator linked to thymic function (PMID 41373628).
What class of peptide is thymosin alpha-1?▾
It is classified as an immunomodulatory peptide rather than a metabolic or growth-related one. Reviews summarise its reported activity across antigen presentation, T-cell function and innate signalling, and have argued for framing it broadly within immuno-oncology rather than only in antiviral contexts (PMID 36871535, PMID 36812669). Study endpoints in this field are typically immune-cell phenotypes and cytokine profiles.
What do laboratory studies report about thymosin alpha-1 and macrophages?▾
A 2022 study reported that thymosin α-1 reversed M2 polarisation of tumour-associated macrophages during efferocytosis (PMID 35364609). A 2024 report described the same directional shift in the setting of oncolytic adenovirus therapy, where researchers reported improved antitumour immunity and therapeutic efficacy in the models used (PMID 39357524). Both were preclinical rather than human outcome studies.
Has thymosin alpha-1 been studied in human cells or patients?▾
Yes, in specific settings. Researchers reported that thymosin alpha 1 mitigated the cytokine-storm profile in blood cells taken from COVID-19 patients and tested ex vivo (PMID 33506065). A double-blind randomised study in severe acute pancreatitis reported improved cellular immunity and a reduced infection rate among enrolled patients (PMID 20549321). Findings are specific to those populations and endpoints.
Are there negative findings for thymosin alpha-1?▾
Yes. A 2018 study tested Tα1 in cystic fibrosis airway epithelia and reported that it did not correct the F508del-CFTR defect, contradicting an earlier claim that the peptide acted as a single-molecule corrector (PMID 29415893). Null results like this are commonly cited to show that broad immunomodulatory activity does not automatically extend to unrelated disease biology.
Do studies describe a safety profile for thymosin alpha-1?▾
The reports summarised here were built around mechanism and efficacy endpoints rather than systematic safety characterisation, so they do not establish a tolerability profile. The randomised pancreatitis study reported immune and infection outcomes (PMID 20549321), while cell-line work reported immunological measures across immune subsets (PMID 40955371). Questions about risk belong with a licensed physician and approved product labelling.
Is thymosin alpha-1 a natural molecule or a synthetic one?▾
Both forms are discussed. The natural peptide is thymus-derived and measurable in serum; a 2016 investigation reported lower circulating thymosin α1 in patients with chronic inflammatory autoimmune diseases than in healthy controls (PMID 27350088). Material used in research is chemically synthesised, and reviews connect age-related thymic decline to interest in Tα1 as a marker of immunosenescence (PMID 41373628).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.